MA35674B1 - Derives de chromone, leur procede de preparation et leurs applications therapeutiques - Google Patents

Derives de chromone, leur procede de preparation et leurs applications therapeutiques

Info

Publication number
MA35674B1
MA35674B1 MA34616A MA34616A MA35674B1 MA 35674 B1 MA35674 B1 MA 35674B1 MA 34616 A MA34616 A MA 34616A MA 34616 A MA34616 A MA 34616A MA 35674 B1 MA35674 B1 MA 35674B1
Authority
MA
Morocco
Prior art keywords
preparation
therapeutic applications
chromone derivatives
chromone
derivatives
Prior art date
Application number
MA34616A
Other languages
English (en)
Inventor
Thierry Imbert
Jean-Pierre Rieu
Jean-François Patoiseau
Pierre Sokoloff
Ludovic Leriche
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA35674B1 publication Critical patent/MA35674B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrane Compounds (AREA)

Abstract

La présente invention porte sur des dérivés de chromone, sur leur préparation, sur leurs compositions pharmaceutiques et sur leur application comme ligands dopaminergiques d3 en tant que médicaments pour des troubles du système nerveux central.
MA34616A 2009-09-01 2012-02-09 Derives de chromone, leur procede de preparation et leurs applications therapeutiques MA35674B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0955944A FR2949465B1 (fr) 2009-09-01 2009-09-01 Derives chromones, leur procede de preparation et leurs applications therapeutiques
PCT/IB2010/053895 WO2011027289A1 (fr) 2009-09-01 2010-08-31 Dérivés de chromone, leur procédé de préparation et leurs applications thérapeutiques

Publications (1)

Publication Number Publication Date
MA35674B1 true MA35674B1 (fr) 2014-12-01

Family

ID=41403421

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34616A MA35674B1 (fr) 2009-09-01 2012-02-09 Derives de chromone, leur procede de preparation et leurs applications therapeutiques

Country Status (32)

Country Link
US (1) US8546402B2 (fr)
EP (1) EP2470520B1 (fr)
JP (1) JP5786229B2 (fr)
KR (1) KR101663635B1 (fr)
CN (1) CN102482251B (fr)
AR (1) AR078114A1 (fr)
AU (1) AU2010290871B2 (fr)
BR (1) BR112012003741B1 (fr)
CA (1) CA2771061C (fr)
CL (1) CL2012000516A1 (fr)
CO (1) CO6491096A2 (fr)
DK (1) DK2470520T3 (fr)
ES (1) ES2428751T3 (fr)
FR (1) FR2949465B1 (fr)
GE (1) GEP20146080B (fr)
HK (1) HK1170724A1 (fr)
HR (1) HRP20130832T1 (fr)
IL (1) IL217729A (fr)
MA (1) MA35674B1 (fr)
MX (1) MX2012002543A (fr)
MY (1) MY162345A (fr)
NZ (1) NZ597930A (fr)
PL (1) PL2470520T3 (fr)
PT (1) PT2470520E (fr)
RU (1) RU2545214C2 (fr)
SG (1) SG178198A1 (fr)
SI (1) SI2470520T1 (fr)
TN (1) TN2012000049A1 (fr)
TW (1) TWI510483B (fr)
UA (1) UA109260C2 (fr)
WO (1) WO2011027289A1 (fr)
ZA (1) ZA201200770B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010015518A2 (fr) 2008-08-05 2010-02-11 Boehringer Ingelheim Interntional Gmbh Naphtyridines à substitution 4-diméthylamino-phényle, et leur utilisation en tant que médicaments
AP3622A (en) 2009-05-13 2016-03-02 Gilead Sciences Inc Antiviral compounds
BR112012018865A2 (pt) 2010-01-29 2016-04-12 Boehringer Ingelheim Int naftiridinas substituídas e seu uso como inibidores de quinase syk
CN103827090B (zh) 2011-07-26 2016-04-20 勃林格殷格翰国际有限公司 取代的喹啉及其作为药物的用途
JP6073897B2 (ja) 2011-09-16 2017-02-01 ギリアド ファーマセット エルエルシー Ｈｃｖを処置するための方法
ES2771458T3 (es) 2013-01-31 2020-07-06 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
PL3650014T3 (pl) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Preparat złożony dwóch związków przeciwwirusowych
JP6419826B2 (ja) * 2013-12-13 2018-11-07 ピエール、ファーブル、メディカマン 自閉症スペクトラム障害の治療のためのドーパミンｄ３受容体拮抗薬としてのクロモン誘導体
CN111295191A (zh) 2017-11-03 2020-06-16 皮埃尔法布雷医药公司 精神分裂症的治疗
PT3762368T (pt) 2018-03-08 2022-05-06 Incyte Corp Compostos de aminopirazina diol como inibidores de pi3k-y
WO2020010003A1 (fr) 2018-07-02 2020-01-09 Incyte Corporation DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ
CN112220782B (zh) * 2020-11-11 2021-08-20 中国人民解放军军事科学院军事医学研究院 1,2,4-三甲氧基苯在防治创伤后应激障碍中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089497A (en) * 1990-09-20 1992-02-18 Warner-Lambert Company Substituted piperazines as central nervous system agents
DE4233963A1 (de) * 1992-10-08 1994-04-14 Schwabe Willmar Gmbh & Co Neue Benzopyranone, Verfahren zu ihrer Herstellung und Verwendung
DK1519726T3 (da) * 2002-07-04 2007-06-04 Sanol Arznei Schwarz Gmbh Heteroarencarboxamider til anvendelse som dopamin-D3-ligander til behandling af CNS-sygdomme
EP1683790A1 (fr) * 2005-01-24 2006-07-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dérivés de 3,4-dihydro-2-naphtamide comme ligands selectifs de la dopamine D3
AU2006215785A1 (en) * 2005-02-18 2006-08-24 Arpida Ag Novel processes for the preparation of a benzofuran
FR2903986A1 (fr) * 2006-07-21 2008-01-25 Pierre Fabre Medicament Sa Nouveaux derives chromenes ou thiochromenes carboxamides, leur procede de preparation et leurs applications en therapeutique

Also Published As

Publication number Publication date
HRP20130832T1 (en) 2013-10-11
US20120157463A1 (en) 2012-06-21
JP2013503848A (ja) 2013-02-04
AU2010290871B2 (en) 2014-06-26
IL217729A (en) 2015-09-24
MX2012002543A (es) 2012-06-25
EP2470520A1 (fr) 2012-07-04
HK1170724A1 (en) 2013-03-08
GEP20146080B (en) 2014-04-25
CL2012000516A1 (es) 2012-08-31
KR101663635B1 (ko) 2016-10-10
TW201111369A (en) 2011-04-01
KR20120060835A (ko) 2012-06-12
TWI510483B (zh) 2015-12-01
SG178198A1 (en) 2012-03-29
FR2949465A1 (fr) 2011-03-04
MY162345A (en) 2017-06-15
IL217729A0 (en) 2012-03-29
RU2012106743A (ru) 2013-10-10
WO2011027289A1 (fr) 2011-03-10
CO6491096A2 (es) 2012-07-31
PL2470520T3 (pl) 2013-10-31
EP2470520B1 (fr) 2013-07-17
DK2470520T3 (da) 2013-08-26
FR2949465B1 (fr) 2011-08-12
TN2012000049A1 (en) 2013-09-19
CN102482251A (zh) 2012-05-30
US8546402B2 (en) 2013-10-01
RU2545214C2 (ru) 2015-03-27
BR112012003741B1 (pt) 2021-06-22
CA2771061A1 (fr) 2011-03-10
UA109260C2 (uk) 2015-08-10
ZA201200770B (en) 2012-10-31
AR078114A1 (es) 2011-10-12
NZ597930A (en) 2013-09-27
AU2010290871A1 (en) 2012-02-16
JP5786229B2 (ja) 2015-09-30
SI2470520T1 (sl) 2013-10-30
CN102482251B (zh) 2015-01-28
CA2771061C (fr) 2015-06-02
ES2428751T3 (es) 2013-11-11
PT2470520E (pt) 2013-10-02

Similar Documents

Publication Publication Date Title
MA35674B1 (fr) Derives de chromone, leur procede de preparation et leurs applications therapeutiques
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA38146B1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA30630B1 (fr) Nouveaux derives chromenes ou thiochromenes carboxamides, leur procede de preparation et leurs applications en therapeutique.
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA39783B1 (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
WO2008152099A3 (fr) Aryl/hétarylamides en tant que modulateurs du récepteur ep2
TN2014000301A1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA33730B1 (fr) Procédés de synthèse pour des composés spiro-oxindoles
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
WO2008152093A3 (fr) Diaminopyrimidines en tant que modulateurs du récepteur ep2
MA34474B1 (fr) Agonistes de gpr40
MA37798B1 (fr) 4-méthyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphtalènes
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA35444B1 (fr) Ligands du récepteur ep1
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
MA38076A1 (fr) Dérivés d'oxazolidin-2-one-pyrimidine
FR2981933B1 (fr) Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
MA20150350A1 (fr) Dérivés isoxazolidine
MA37879B1 (fr) Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant
MA38487A1 (fr) Agents séquestrants de précurseurs de produits terminaux de glycation avancée (age)